Literature DB >> 1804788

Once daily versus every two week multidose ofloxacin in patients with acute exacerbations of chronic respiratory disease.

A Watanabe1.   

Abstract

Two different oral ofloxacin regimens, daily single-dose treatment with 200 mg (Regimen I) and every two week multidose treatment with 3 x 200 mg/day (Regimen II), were compared to evaluate the efficacy of quinolone regimens in controlling acute exacerbations of chronic respiratory tract infections. Fifty-one patients were evaluated in the study: 28 in Regimen I and 23 in Regimen II. The corrected mean incidence of exacerbation per case during the six months before and during the study was reduced from 2.45 to 0.48 in Regimen I, and from 2.79 to 1.0 in Regimen II. The development of resistant strains was not found to be a problem. We conclude that the long-term administration of new quinolones, especially the daily single-dose regimen with 200 mg of ofloxacin, is useful in controlling acute exacerbations of chronic respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804788     DOI: 10.1007/BF01715833

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs; C Baur
Journal:  Eur J Respir Dis Suppl       Date:  1986

2.  Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study.

Authors:  C Grassi; G Gialdroni Grassi; P Mangiarotti
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Long-term effects of ofloxacin on clinical courses in patients with diffuse panbronchiolitis.

Authors:  A Sato; I Shichi; M Iwata; T Suda; A Okano; K Chida
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

4.  Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.

Authors:  R E McCabe; D Schlossberg; G R Donowitz; W M Scheld; S R Zellner; L B Lindenberg; J H Armstrong; M E Ein
Journal:  Clin Ther       Date:  1989 May-Jun       Impact factor: 3.393

5.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

6.  Ciprofloxacin in acute exacerbations of chronic bronchitis.

Authors:  J A Hoogkamp-Korstanje; S J Klein
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

7.  Respiratory infections: clinical experiences with the new quinolones.

Authors:  B I Davies; F P Maesen
Journal:  Pharm Weekbl Sci       Date:  1987-12-11
  7 in total
  4 in total

1.  Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.

Authors:  K Watanabe; M Yoshida; T Ishibashi; H Yamada; M Kido; T Hirose; F Maeda; Y Matsuzaki
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 2.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

3.  Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).

Authors:  Samantha C Herath; Rebecca Normansell; Samantha Maisey; Phillippa Poole
Journal:  Cochrane Database Syst Rev       Date:  2018-10-30

Review 4.  Continuous versus intermittent antibiotics for bronchiectasis.

Authors:  Tim Donovan; Lambert M Felix; James D Chalmers; Stephen J Milan; Alexander G Mathioudakis; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.